U.S., March 7 -- ClinicalTrials.gov registry received information related to the study (NCT06860529) titled 'Serplulimab Combined with Chemotherapy for Early-stage HR+/HER2- Breast Cancer' on Feb. 05.
Brief Summary: The neoadjuvant treatment options commonly used for HR+/HER2- breast cancer are mainly anthracycline sequential or combined with paclitaxel chemotherapy regimens. Several clinical studies have confirmed that albumin paclitaxel is more effective than solvent-based paclitaxel, and therefore, albumin paclitaxel in combination with epirubicin has also become a commonly used chemotherapy regimen in clinical practice.
The aim of this study was to explore the efficacy and safety of the Serplulimab combined with nab-paclitaxel and epi...